Followers | 9 |
Posts | 750 |
Boards Moderated | 0 |
Alias Born | 10/19/2008 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, February 21, 2014 10:29:30 AM
I have been interested in infectious diseases prior to hearing about NNVC. I was amazed by the efficacy with rabies testing in Vietnam. Anyone who really understands the meaning of that should be looking at NNVC very seriously.
While not personally in the medical field from a professional standpoint, I know and have close contacts with those that are. I am also learned enough in the sciences to understand mechanisms and concepts related to my interests.
I know for a fact that Dr. Harris is very well renowned. Her papers and studies into the pathogenesis and epidemiology of infectious diseases have been of benefit to the medical community for years. Her work with the dengue fever virus is probably second to none. If she, using a non scientific descriptor, poo pooed, the NNVC approach after studying it, I would have swung my doubts the other way. Yet the opposite occurred and her honest interest in transferring advanced technology to the developing world and building on the science is from practical purposes unmatched.
From a bio/pharmaceutical engineering standpoint I am intrigued by NNVCs ability to impart specific ligands to billions of nano particles. I would like very much to review the science with them directly if I could. Scale up could be an issue for them. That might be one of the areas more funding and focused approach could help. Just postulating though.
I am ultra happy that Dr. Harris is on board for another round of investigations. Believe me in totality, if she did not think it was worth it, she would not give it the time. She not only has better things to do with her time, but the brains and drive to do it with.
Wishing all the best of good buys.
HS
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM